Sheridan Limited established a SARS program that entitled its new president, Carol Garcia, to receive cash for the difference between the Sheridan common shares' fair value and a pre-established price of $33 (also fair value on December 31, 2022), on 43,000 SARs. The date of grant is December 31, 2022, and the required employment (service) period is four years. The common shares' fair value fluctuated as follows: December 31, 2023, $36; December 31, 2024, $39; December 31, 2025, $46; December 31, 2026, $36; and December 31, 2027, $49. Sheridan recognizes the SARS in its financial statements. Carol exercised half of the SARS on June 1, 2028, when the share price was $47. Assume that Sheridan follows ASPE. (c) Prepare the entry at June 1, 2028, for the exercise of the SARS.

Intermediate Accounting: Reporting And Analysis
3rd Edition
ISBN:9781337788281
Author:James M. Wahlen, Jefferson P. Jones, Donald Pagach
Publisher:James M. Wahlen, Jefferson P. Jones, Donald Pagach
Chapter15: Contributed Capital
Section: Chapter Questions
Problem 6P
icon
Related questions
Question

Do not give answer in image 

Question 3
Sheridan Limited established a SARS program that entitled its new president, Carol Garcia, to receive
cash for the difference between the Sheridan common shares' fair value and a pre-established price of
$33 (also fair value on December 31, 2022), on 43,000 SARs. The date of grant is December 31, 2022,
and the required employment (service) period is four years. The common shares' fair value fluctuated
as follows: December 31, 2023, $36; December 31, 2024, $39; December 31, 2025, $46; December 31,
2026, $36; and December 31, 2027, $49. Sheridan recognizes the SARS in its financial statements.
Carol exercised half of the SARS on June 1, 2028, when the share price was $47. Assume that Sheridan
follows ASPE.
(c) Prepare the entry at June 1, 2028, for the exercise of the SARS.
Date
Account Titles and Explanation
06/01/28 Liability under Share Appreciation Rights Plans
Cash (F)
Compensation Expense
Number of SARS granted and vested (A)
Number of SARS exercised on June 1, 2028 (B)
Pre-established price (C)
Share price as on June 1, 2028 (D)
Debit
Difference b/w share price on June 1, 2028 and pre-established price (E = D-C)
Amount of SARS Exercised - Cash (F= E*B)
$
ess
$
Credit
301,000
43,000
21,500
33
47
14
$
$ 301,000
Transcribed Image Text:Question 3 Sheridan Limited established a SARS program that entitled its new president, Carol Garcia, to receive cash for the difference between the Sheridan common shares' fair value and a pre-established price of $33 (also fair value on December 31, 2022), on 43,000 SARs. The date of grant is December 31, 2022, and the required employment (service) period is four years. The common shares' fair value fluctuated as follows: December 31, 2023, $36; December 31, 2024, $39; December 31, 2025, $46; December 31, 2026, $36; and December 31, 2027, $49. Sheridan recognizes the SARS in its financial statements. Carol exercised half of the SARS on June 1, 2028, when the share price was $47. Assume that Sheridan follows ASPE. (c) Prepare the entry at June 1, 2028, for the exercise of the SARS. Date Account Titles and Explanation 06/01/28 Liability under Share Appreciation Rights Plans Cash (F) Compensation Expense Number of SARS granted and vested (A) Number of SARS exercised on June 1, 2028 (B) Pre-established price (C) Share price as on June 1, 2028 (D) Debit Difference b/w share price on June 1, 2028 and pre-established price (E = D-C) Amount of SARS Exercised - Cash (F= E*B) $ ess $ Credit 301,000 43,000 21,500 33 47 14 $ $ 301,000
Expert Solution
steps

Step by step

Solved in 3 steps with 2 images

Blurred answer
Knowledge Booster
Evaluating Executive Compensations
Learn more about
Need a deep-dive on the concept behind this application? Look no further. Learn more about this topic, accounting and related others by exploring similar questions and additional content below.
Similar questions
  • SEE MORE QUESTIONS
Recommended textbooks for you
Intermediate Accounting: Reporting And Analysis
Intermediate Accounting: Reporting And Analysis
Accounting
ISBN:
9781337788281
Author:
James M. Wahlen, Jefferson P. Jones, Donald Pagach
Publisher:
Cengage Learning